Author:
Stengel C,Newman S P,Leese M P,Potter B V L,Reed M J,Purohit A
Publisher
Springer Science and Business Media LLC
Reference33 articles.
1. Correnti M, Cavazza ME, Guedez N, Herrera O, Suarez-Chacon NR (1995) Expression of the multidrug-resistance (MDR) gene in breast cancer. J Chemother 7: 449–451
2. Ferlini C, Raspaglio G, Mozzetti S, Cicchillitti L, Filippetti F, Gallo D, Fattorusso C, Campiani G, Scambia G (2005) The seco-taxane IDN5390 is able to target class III beta-tubulin and to overcome paclitaxel resistance. Cancer Res 65: 2397–2405
3. Foster PA, Stengel C, Ali T, Leese MP, Potter BVL, Reed MJ, Purohit A, Newman SP (2008) A comparison of two orally bioavailable anti-cancer agents, IRC-110160 and STX140. Anticancer Res 28: 1483–1491
4. Gan PP, Pasquier E, Kavallaris M (2007) Class III beta-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer. Cancer Res 67: 9356–9363
5. Giannakakou P, Sackett DL, Kang YK, Zhan Z, Buters JT, Fojo T, Poruchynsky MS (1997) Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 272: 17118–17125
Cited by
164 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献